Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kalaris Therapeutics, Inc.KLRS · Entity 6805 | Director | June 03, 2026 | June 04, 2026 |
| TuHURA Biosciences, Inc./NVDMPI · Entity 6601 | Director | June 26, 2020 | June 30, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kalaris Therapeutics, Inc.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2036-06-02 | Direct | 9,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 9,000 · Balance 9,000 F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
TuHURA Biosciences, Inc./NV
Report date June 26, 2020 · Filed June 30, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.61 · Expires 2029-09-05 | Direct | 75,000 |
Reported balance
After 2020-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-26 · Grant · Acquired 39,567 · Balance 75,000 F1: On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020. F2: The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020.
F2: The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 20:36 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001193125-26-257556 · ownership.xml · derivative · entry 1 Ferrara Napoleone · CIK 0001744779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 21:03 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0000950170-25-053368 · ownership.xml · derivative · entry 1 Ferrara Napoleone · CIK 0001744779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2035-04-09 F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service. Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 21:45 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantCommon Stock | 504,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-041498 · ownership.xml · nonDerivative · entry 1 Ferrara Napoleone · CIK 0001744779 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 504,000 F1 · date: Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the Merger). F2 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:09 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 39,567 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001213900-20-016306 · ownership.xml · derivative · entry 1 Ferrara Napoleone · CIK 0001744779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 39,567 shares Expires 2029-09-05 F1 · kind: On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020. F2 · derivative.exercise_date: The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 20:52 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 35,433 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000905718-19-000771 · delmarph_fm4sept52019.xml · derivative · entry 2 Ferrara Napoleone · CIK 0001744779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,433 Underlying: Common Stock · 35,433 shares Expires 2029-09-05 F2 · derivative.exercise_date: The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 20:52 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 39,567 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000905718-19-000771 · delmarph_fm4sept52019.xml · derivative · entry 1 Ferrara Napoleone · CIK 0001744779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,567 Underlying: Common Stock · 39,567 shares Expires 2029-09-05 F1 · derivative.exercise_date: Subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the next annual meeting, the shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019. Read SEC document |
| April 30, 2019 Filed May 1, 2019 22:31 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | Disposition to issuerPerformance Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-007625 · ownership.xml · derivative · entry 1 Ferrara Napoleone · CIK 0001744779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2022-07-07 F1 · derivative.exercise_price: Each performance stock unit represents the right to receive one share of common stock, to vest upon achievement of specified targets related to the Company's financial performance. Such performance stock units were unvested. F1 · derivative.exercise_date: Each performance stock unit represents the right to receive one share of common stock, to vest upon achievement of specified targets related to the Company's financial performance. Such performance stock units were unvested. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 21:40 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001213900-18-015519 · ownership.xml · derivative · entry 1 Ferrara Napoleone · CIK 0001744779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-11-08 F1 · derivative.exercise_date: The shares subject to the option vest in twelve (12) equal monthly installments beginning on December 8, 2018. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 23:51 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantPerformance Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-008296 · ownership.xml · derivative · entry 2 Ferrara Napoleone · CIK 0001744779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-07-07 F2 · derivative.exercise_price: Each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. F2 · derivative.exercise_date: Each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. Read SEC document |
| June 22, 2018 Filed Jun 26, 2018 23:51 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 54,514 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001213900-18-008296 · ownership.xml · derivative · entry 1 Ferrara Napoleone · CIK 0001744779 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,514 Underlying: Common Stock · 54,514 shares Expires 2028-06-22 F1 · derivative.exercise_date: One-third of the award vests on May 31, 2019, the remainder of the award vests in equal installments each three months thereafter, commencing on August 31, 2019 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.